Clinical Trial Update: Evaluating Pyrroloquinoline Quinone (PQQ) for Improving Obese Pregnancy Outcomes [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 trial evaluating pyrroloquinoline quinone (PQQ) for improving outcomes in maternal obesity has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Maternal Obesity

Drugs mentioned

• Pyrroloquinoline quinone (PQQ) (Pyrroloquinoline quinone)

Snippet

Sponsor: University of Oklahoma | Conditions: Maternal Obesity | EARLY_Phase 1 | Status: WITHDRAWN